The Department of Justice has decided to extend for an additional year a deferred prosecution agreement reached in 2012 with Biomet after the medical device maker self-reported additional potential violations of the Foreign Corrupt Practices Act, the company said last week in a Form 8-K.
In 2012, Biomet entered into a DPA with the Justice Department, and a parallel consent agreement with the Securities and Exchange Commission for possible violations of the FCPA. Then, in October 2013, Biomet became aware of certain alleged improprieties regarding its operations in Brazil and Mexico, including alleged improprieties that predated the entry of the DPA.
